Better Health for All

Newron Pharmaceuticals focuses on developing novel therapies for central and peripheral nervous system diseases, including Parkinson's disease (Xadago®) and schizophrenia (Evenamide), with its entire business devoted to health improvement. Evenamide, a first-in-class glutamate modulator, has shown significant efficacy in clinical trials for treatment-resistant schizophrenia (TRS), with over 70% of patients experiencing a clinically important reduction in disease severity and 25% achieving remission in Study 014/015.

This innovative therapeutic option aims to address positive, cognitive, and negative symptoms, a key advantage over existing antipsychotics. The company demonstrates a high investment in health innovation, with R&D expenses of EUR 13.6 million in 2024, representing 26.46% of its EUR 51.4 million total revenues. Evenamide has a favorable safety and tolerability profile, with no new or specific safety concerns raised in Study 008A, and a low incidence of treatment-emergent adverse events in Study 014/015. Newron maintains strong healthcare data responsibility, aligning with GDPR, appointing a Data Protection Officer, and reporting no data breaches in 2022, 2023, or 2024. It also started a program in 2025 to continuously test IT infrastructure security. The company demonstrates patent flexibility through agreements allowing generic market entry for Xadago in the US by December 2027 and licensing agreements for Evenamide in South Korea, Japan, and other Asian territories. Clinical trials are conducted with strong ethical frameworks, including randomized, double-blind, placebo-controlled designs, Independent Eligibility Assessment Committees, FDA and IRB approvals, adherence to ICH requirements, and a commitment to diversity and inclusion in trials. Newron conducts trials in developing countries and guarantees drug access during trials and open-label phases. The company makes efforts to reduce environmental externalities by using low-emission company cars (75% electric by end 2024) and offsetting 53.2 tons of CO2 emissions from employee flights in 2024.

Fair Money & Economic Opportunity

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the research, development, and commercialization of novel therapies.

The provided articles consistently describe the company's activities as related to drug development, clinical trials, and financial performance within the pharmaceutical sector. There is no evidence in any of the articles that Newron Pharmaceuticals offers lending, insurance, or other financial services to consumers or businesses. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to the company's core business.

Fair Pay & Worker Respect

Newron Pharmaceuticals reported zero accidents and zero fatalities at its headquarters for 2022, 2023, and 2024.

The company also recorded no human rights or labor law violations in 2023 or 2024. For pay equity, the average salary difference between female and male middle management (director level) was less than 2% in favor of females in 2023. The voluntary employee turnover rate for 2023 was approximately 8.7%, with two employees leaving out of an average headcount of 23. Regarding health insurance, US-based employees receive high-quality employer-funded health insurance, but the coverage rate for the entire workforce is not specified. The company has a total of 22 employees globally, with 19 in Italy and 3 in the USA.

Honest & Fair Business

Newron Pharmaceuticals reported no identified cases of corruption and no sanctions imposed for material breaches of environmental, social, or other laws in both 2023 and 2024.

The company issued a new anti-corruption and bribery policy in 2024, and all employees were trained on it. The Code of Conduct, approved in September 2023 and reviewed annually, applies to all Board members, Management Team members, and employees. In 2024, the company introduced a whistleblowing service and a dedicated platform, which became available to employees and stakeholders in early 2025. All employees received training on this policy and service. Cyber security protocols and actions were reviewed and approved by external experts in 2024, as in previous years.

Kind to Animals

Newron Pharmaceuticals uses animal models in its preclinical research, specifically a neurodevelopmental methylazoxymethanol acetate animal model and studies in rats and dogs for compounds like evenamide and sarizotan.

The company's research on evenamide involved injecting methylazoxymethanol acetate into pregnant rats. While the articles discuss general FDA plans to phase out animal testing and encourage alternative methods, there is no evidence that Newron Pharmaceuticals itself employs non-animal testing methods. The FDA expressed concern over the company's studies in rats and dogs, leading to a request to delay clinical trials. The company's policy prohibits discretionary animal testing, but legal mandates still override the use of alternatives.

Planet-Friendly Business

Newron Pharmaceuticals reported no sanctions for material breaches of environmental laws in 2022 and 2023.

The company compensated 53.2 tons of CO2 emissions for employee flights in 2024, collaborating with Foundation Myclimate for these offsets. However, the quality rating of these offsets is not specified, and the compensated amount represents only a portion of total emissions.

Respect for Cultures & Communities

The provided articles do not contain specific quantitative data or concrete facts related to Newron Pharmaceuticals' performance on any of the KPIs for 'Respect for Cultures & Communities'. Article 0 explicitly states a lack of specific quantitative data on community engagement, cultural impact assessments, grievance mechanisms, FPIC participation, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license to operate, charitable giving, or community fund allocation.

While 'diversity and inclusion training' is mentioned as an ESG goal for 2023, there is no evidence of completion or specific mention of cultural sensitivity training. Therefore, no KPIs can be scored.

Safe & Smart Tech

Newron Pharmaceuticals reported no data breaches in 2024 or 2023.

The company uses encryption for communications and monitors for illicit behavior to ensure website security. Its cookie and privacy policies are in accordance with GDPR EU 2016/679, and a Data Protection Officer has been appointed. Users can withdraw consent for profiling cookies and exercise GDPR rights such as access, correction, deletion, or restriction of personal data. The company states that the retention period for personal data is limited to what is strictly necessary, and data for email alerts is deleted upon unsubscription. However, analytical cookies have a retention period of up to 13 months, and some technical cookies up to 1 year. The company has a program to continuously test the security of its IT infrastructure, which started in early 2025. The privacy notice was updated on April 4, 2024.